News >

Sorting Through Unanswered Questions in Ovarian Cancer

Brandon Scalea
Published: Monday, Jun 10, 2019

Thanh H. Dellinger, MD

Thanh H. Dellinger, MD

There are no clear indications driving which patients with newly diagnosed advanced ovarian cancer should receive intraperitoneal (IP) chemotherapy, dose-dense chemotherapy, or hyperthermic intraperitoneal chemotherapy (HIPEC); therefore, physicians currently rely on clinical features, patient characteristics, and even biases to make treatment decisions, explained Thanh H. Dellinger, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x